GlassScriptPhysician profile
Adam Liparoto
NPI 1912556762
$4,270.79
in general payments reported to CMS, 2019-2025
18 companies · $929 in 2025
The $929 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $975 · 2023: $913 · 2024: $1,178 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,809 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,809.06 |
| Education | $210.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $898.80 | 2023-2025 | Lumryz |
| Viiv Healthcare Company | $876.53 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Jazz Pharmaceuticals INC. | $777.37 | 2023-2025 | |
| Harmony Biosciences LLC | $555.91 | 2023-2025 | Wakix |
| Gilead Sciences, INC. | $350.81 | 2021-2023 | |
| Janssen Biotech, INC. | $134.76 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $126.80 | 2021-2023 | Delstrigo, Pifeltro |
| Axsome Therapeutics, INC. | $121.18 | 2023-2025 | Sunosi |
| Janssen Products, LP | $99.95 | 2021 | |
| Pfizer INC. | $60.09 | 2023 | |
| Napo Pharmaceuticals INC | $49.73 | 2021-2022 | |
| Dynavax Technologies Corporation | $46.02 | 2022-2023 | Heplisav-B |
| Vbi Vaccine (Delaware) INC. | $44.71 | 2022 | |
| Fisher & Paykel Healthcare INC | $38.96 | 2023-2025 | Fisher & Paykel Healthcare |
| Lilly USA, LLC | $34.77 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $19.26 | 2023 | |
| Hologic Sales and Service, LLC | $17.64 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.50 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Liparoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.